New York, NY -- (SBWIRE) -- 11/02/2013 -- StockMarketIntel.com issues a special report on the following stocks: Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Halozyme Therapeutics, Inc. (NASDAQ:HALO), ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) recently gained 2.50%, while trading on 1.14M shares, at the price of $14.74. The stock changed hands in a range of $14.20 to $14.95 up till now, bringing its market capitalization at about $879.35 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $4.35 and was moved to the maximum level of $15.29. Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company’s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs.
For How Long RPTP will Fight for Profitability? Read This Trend Analysis report
Halozyme Therapeutics, Inc. (NASDAQ:HALO) recently down -0.60% while trading on 1.15M shares, at the price of $11.58. The stock changed hands in a range of $11.47 to $11.88 up till now. If we look at its trading history of the past 52 weeks, the share price suffered a low of $4.80 and was moved to the maximum level of $12.60. Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix. The Company’s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology.
Has HALO Found The Bottom And Ready To Gain Momentum? Find Out Here
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) recently down -0.48% and was moving within a range of $32.65 -$34.82. Its current trading price is $33.11. The share price hit its 52-week low of $7.55 and $39.83 was the best price. The stock completed the day with a total volume of 1.14M shares, versus an average volume of 1.53M shares. Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma .
Why Should Investors Buy ISIS After the Recent Fall? Just Go Here and Find Out
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) down -1.96% in its current trading activity, bringing its market capitalization around $232.81 million. The total number of shares that changed hands during the current session up till now was 1.12 million shares, as compared to average trading volume of 740,779.00 shares. The share price after opening at $7.14 made a high of $7.30 and hovered above $6.81, while its recent trading price was $7.02. Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders.
Will VNDA Get Buyers Even After The Recent Rally? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)